Provides 3x leveraged exposure to the daily performance of the S&P Biotechnology Select Industry Index. Now — the numbers.
An investor who bought at the very peak is down 81% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
It pays out $1.34 per share each year — regular cash for whoever holds the stock.
This stock swings about 3 times as much as the market average. Big rallies — and big drops — can both happen fast.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 0/100.
We grade companies — revenue, margins, balance sheets. This is a fund, so there is no report card to give. That is not a low grade; it is a different kind of thing.
One-line summary: a basket, not a business. Judge it by what it holds.